Elasmogen

About Elasmogen

Elasmogen is a Aberdeen-based biopharmaceutical company focused on discovering and developing soloMERs, proprietary VNAR-based biologics, to treat autoimmune, inflammatory diseases and cancer. The company leverages its soloMER technology platform to create disease-targeting therapeutic agents with differentiated binding and multi-functional capabilities. Their research and development activities span identifying targets, preclinical evaluation, and licensing opportunities to collaborators worldwide. Elasmogen emphasizes fast reformatting and novel mechanisms of action to improve patient outcomes in autoimmune and oncology indications.